Content by Keyword: Drugs, Medical Devices, and Pharmacy Services

  • Home
  • Drugs, Medical Devices, and Ph...
  • print
  • email
  • twitter
  • compact
Report page
Case Studies

Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Case Studies

The purpose of the case studies is to gain insight into the experiences of companies that are relevant to developing and marketing medications for drug abuse and addiction. These include two in-depth case studies of LAAM for heroin addiction and naltrexone for heroin addiction (as Trexan) and alcohol addiction (as ReVia), as well as two smaller ca
Report page
Scenarios of Company Decision Making

Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Scenarios of Company Decision Making

This report presents several scenarios of pharmaceutical company decision making regarding whether to undertake projects to develop pharmacotherapies for cocaine addiction under various sets of market conditions. Using a quantitative model developed by The Lewin Group, the market conditions were translated into financial and other parameters to ge
Report page
Translating Market Barriers and Policy Options

Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Translating Market Barriers and Policy Options into Financial Parameters

Pharmaceutical companies' decisions to pursue new products are based largely on financial considerations inherent in risk-reward tradeoffs. Despite their diversity, most market barriers can be interpreted as having a direct effect on one or more financial parameters that are factored into these decisions. Similarly, most policy options that exist
Report page
Basic Relationships of Price, Market Size, and

Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Basic Relationships of Price, Market Size, and Revenues

Pharmaceutical companies' decisions to pursue new products are based largely on financial considerations inherent in risk-reward tradeoffs. Financial indicators such as product net present value (NPV) and peak annual revenue (PAR) usually drive investment decisions. Beyond the appreciable risk associated with developing and marketing any new medic
Report page
Expectations of Low Market Penetration

Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Expectations of Low Market Penetration

The proportion of the entire population of heavy substance abusers that is considered to be a realistic target market for pharmacotherapy is small relative to the target market of medications for other diseases. Although there are other clinical conditions for which the market penetration of medications is proportionately low, the absolute magnitu
Report page
Estimate of Cocaine Users in the U.S.

Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Estimate of Cocaine Users in the U.S.

There are more than 2 million addicted or "heavy" cocaine users. Of these, as many as 800,000 to 900,000 may enter treatment at least once in a given year. On any given day, roughly 250,000 cocaine abusers are enrolled in treatment (i.e., who are at a residential facility or have been served at an ambulatory treatment center within the previous 30
Report page
Principal Findings

Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Principal Findings

Report page
Methods

Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Methods

This study relied on several types of sources for information about cocaine pharmacotherapies and the market barriers to their development. These included:
Report page
Principal Conclusions

Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Principal Conclusions

Under current conditions, pursuing development of a new cocaine pharmacotherapy via a typical full product development cycle is not economically viable from the standpoint of industry. Although a variety of hurdles or procedural impediments may affect prospects for new pharmacotherapy development in this area, most of these are regarded as surmoun
Report page
Purpose

Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Purpose

The purpose of this project was to produce an analysis of the market barriers to the development of pharmacotherapies for substance abuse and addiction, and for cocaine abuse and addiction in particular. The analysis is intended to provide ASPE with information related to four areas:
Report page
Executive Summary

Market Barriers to the Development of Pharmacotherapies for the Treatment of Cocaine Abuse and Addiction: Final Report. Executive Summary

PDF report
State Government Employer-Sponsored Prescription

State Government Employer-Sponsored Prescription Drug Coverage Strategies to Optimize Cost Control and Use of Prescription Drugs

Updated Analyses of Trends in Use of Assistive

Updated Analyses of Trends in Use of Assistive Devices

Updated Analyses of Trends in Use of Assistive Devices Executive Summary Brenda Spillman Urban Institute January 7, 2013 REVISED January 20, 2014
Accelerating Adoption of Assistive Technology to

Accelerating Adoption of Assistive Technology to Reduce Physical Strain among Family Caregivers of the Chronically Disabled Elderly Living at Home

Analysis of Supply, Distribution, Demand, and

Analysis of Supply, Distribution, Demand, and Access Issues Associated with Immune Globulin Intravenous (IGIV)

Contents IGIV Supply and Distribution - Key Findings IGIV Demand - Key Fundings IGIV Access Problems- Key Fundings
Issues in the Design and Implementation of Drug

Issues in the Design and Implementation of Drug Formularies and Therapeutic Classes

As part of the Medicare Part D pharmacy benefit scheduled for implementation in 2006 by the Medicare Prescription Drug, Improvement, and Modernization Act (MMA), beneficiaries will have a choice of private plans administering the benefit.? Although plans are required to provide access to needed drugs, the law does not require plans to provide equa
Options for Defining Medicare Advantage Regions:

Options for Defining Medicare Advantage Regions: An Assessment of Tradeoffs

Contents  
Health Care in Transition:

Health Care in Transition: Technology Assessment in the Private Sector

Health Care in Transition: Technology Assessment in the Private Sector Prepared by: Richard Rettig of the RAND Corporation Office of the Assistant Secretary of Planning and Evaluation Agency for Health Care Policy and Research. July, 1996.
Prescription Drug Coverage, Spending, Utilization

Prescription Drug Coverage, Spending, Utilization, and Prices

Prescription drugs play an ever-increasing role in modern medicine. New medications are improving health outcomes and quality of life, replacing surgery and other invasive treatments, and quickening recovery for patients who receive these treatments. As important as prescription drugs are, not everyone has access to them. The newest drugs are ofte
PDF report
Updated Analyses of Trends in Use of Assistive

Updated Analyses of Trends in Use of Assistive Devices

Over the 20 year period 1984-2004, use of assistive devices by older Americans (age 65 and older) residing in the community increased greatly. In 1984, 72% of chronically disabled older Americans made some use of assistive devices, with or without additional human help to perform activities of daily living (i.e., tasks such as bathing, dressing
  • astdevup.pdf
    export-csvPDF

Pages

Form Approved OMB# 0990-0379 Exp. Date 9/30/2020